Managing Cholesterol: Latest Guideline Updates

Synopsis

Cardiovascular disease remains a leading cause of death in Hong Kong, yet most people are unaware of their risk from high cholesterol, hypertension or diabetes.

Our cardiologist unpacks what the latest guidelines mean for patients:

Clearer LDL targets matched to individual risk
Statins as the proven first line therapy with extra medicines added only when needed
Earlier screening for younger adults and those with a family history
Statins' modest diabetes risk rarely outweighs their heart benefits

Cardiovascular Health in Hong Kong: Why It Matters

Cardiovascular disease (CVD) remains a significant health concern in Hong Kong, ranking as the third leading cause of death and accounting for approximately 12.6% of all registered deaths. Despite this, many individuals are unaware of their underlying risk factors.

Findings from the Population Health Survey 2020–22 highlight a concerning gap in awareness:

41% were unaware they had hypertension
36.5% did not know they had diabetes
Nearly 70% did not realise they had elevated cholesterol levels

These figures underscore the importance of early detection and regular health screening. Many cardiovascular risk factors develop silently, without obvious symptoms, making proactive monitoring essential for timely intervention.

Understanding Dyslipidaemia: A key driver of Heart Disease

Dyslipidemia is the primary driving force behind atherosclerosiscardiovascular disease (ASCVD) and cardiovascular disease (CVD), significantly increasing the risk of heart attacks and strokes. It is characterised by high LDL "bad" cholesterol, high triglycerides, or low HDL "good" cholesterol. Hypercholesterolemia is the most common form of dyslipidemia.

Early intervention, including lifestyle optimisation and pharmacological treatment when indicated, is recommended for patients with dyslipidaemia, especially in younger individuals with familial hypercholesterolaemia (FH) or a strong family history of premature ASCVD.

Common LDL-lowering therapies

Class	Mechanism of Action	Examples
Statins	Inhibits cholesterol production in the liver by competitively blocking the enzyme HMG‑CoA reductase	Atorvastatin Fluvastatin Lovastatin
Cholesterol absorption inhibitor	Reduces cholesterol absorption from the gut by inhibiting the NPC1L1 transporter, limiting both dietary and biliary sterol uptake	Ezetimibe
PCSK9 inhibitor (Monoclonal antibodies)	Enhances LDL cholesterol clearance by binding to PCSK9, thereby preventing the breakdown of LDL receptors and increasing their availability	Alirocumab Evolocumab
ATP citrate lyase inhibitor	Targets upstream cholesterol synthesis by inhibiting ATP citrate lyase, further reducing cholesterol production before the HMG‑CoA reductase step	Bempedoic acid
Bile acid sequestrants	Promotes cholesterol breakdown by reducing bile acid reabsorption in the liver, leading to increased conversion of cholesterol into bile acids	Cholestyr-amine Colesevelam Colestipol

What the Latest Cholesterol Updates Mean for You

Recent updates to international cholesterol guidelines reflect a growing emphasis on earlier prevention, personalised care, and clearer treatment goals. For patients, this means more precise guidance on how to manage cholesterol and reduce long-term cardiovascular risk.

1. Tailored Treatment, Step by Step

Lifestyle changes, such as improving diet, increasing physical activity, and stopping smoking, are the foundation of managing cardiovascular risk. When lifestyle changes alone are not sufficient, medication may be recommended. Treatment is typically approached in a stepwise and individualised manner:

Statins as first-line treatment
Additional non-statin medications including ezetimibe and/or bempedoic acid or PCSK9 mAb, if statin monotherapy is insufficient

This ensures that patients receive the right level of treatment, without unnecessary overtreatment.

2. Statins Remain the Foundation of Treatment

Statins continue to be the first-line and most widely studied treatment for lowering cholesterol and reducing cardiovascular risk.

They are recommended for many patients, including those aged 40-75 years with:

Diabetes
Chronic kidney disease stage 3-4
HIV

Extensive research has consistently shown that statins reduce the risk of heart attack, stroke, and cardiovascular death.

For most individuals, statins are well tolerated, and the benefits of treatment significantly outweigh the side effects and potential risks.

3. Clearer Cholesterol Targets

One of the most important updates is the return of specific LDL cholesterol (“bad cholesterol”) targets, tailored to your individual risk level.

For those at lower risk, the goal is less than 2.6 mmol/L
For higher-risk individuals, the target is below 1.8 mmol/L
For those with existing heart disease or very high risk, the goal is below 1.4 mmol/L

This approach helps ensure that treatment is proportionate to your risk, with more intensive management for those who need it most.

4. Early Prevention Across the Lifespan

The latest guidance also places greater emphasis on younger adults and inherited conditions, such as familial hypercholesterolaemia.

Rather than waiting until later in life, the focus is on identifying risk early and intervening sooner, helping to prevent complications before they develop.

5. Can Statins Cause Diabetes? Here’s the Truth

Some patients are concerned about the link between statins and diabetes. While statins have been associated with a small increase in the risk of developing type 2 diabetes, this is generally seen in individuals who already have underlying risk factors like obesity, impaired fasting glucose and metabolic syndrome.

Importantly, for the majority of patients:

The reduction in cardiovascular risk far outweighs this small increase in diabetes risk, particularly for those with intermediate or higher ASCVD risk
Statins should not be withheld for this reason alone.

Also, your doctor may recommend regular monitoring of blood sugar levels and support lifestyle measures such as maintaining a healthy diet, weight, and activity level.

Key Takeaways

Cardiovascular disease remains a leading health concern in Hong Kong, often driven by silent risk factors such as high cholesterol, hypertension, and diabetes. As many individuals are unaware of their condition, regular screening and early detection are essential.

Dyslipidaemia is a key driver of heart disease but is highly manageable with lifestyle changes and appropriate treatment. The latest cholesterol guidelines highlight several important updates patients should know:

Statins remain the first-line treatment
Clear LDL cholesterol targets based on individual risk
Stepwise addition of therapies if needed
Earlier prevention, including for younger adults and inherited conditions
Balanced guidance on statins and diabetes risk
Greater focus on personalised risk assessment

At OT&P Healthcare, our cardiology specialty services, together with comprehensive health screening and multidisciplinary care, support early diagnosis, risk assessment, and tailored treatment plans. Taking a proactive approach can help you reduce cardiovascular risk and protect your long-term heart health.

Dr Jonathan Fang

Cardiology

MBBS (HKU)
MRCP (UK)
FRCP (Lond)
FHKCP
FHKAM (Medicine)
FACC

View Profile

References

Centre for Health Protection. (2025). 'Non-communicable diseases watch: cardiovascular diseases.' Centre for Health Protection, Department of Health, Hong Kong. Available at: https://www.chp.gov.hk/files/pdf/ncd_watch_sep_2025_en.pdf [Accessed: 23 June 2026].
Du, Z. and Qin, Y. (2023). 'Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies.' Journal of Clinical Medicine, 12(1), p. 363. Available at: https://doi.org/10.3390/jcm12010363.
Blumenthal, R.S., Morris, P.B. et al. (2026). '2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.' Circulation, 153, pp. e1154 to e1276. Available at: https://doi.org/10.1161/CIR.0000000000001423.